RBBP4 and breast carcinoma: For example, a BCL11A peptide inhibitor that blocks the recruitment of RBBP4-BCL11A complexes to BCL11A-targeted genes decreases aldehyde dehydrogenase-positive breast cancer stem cells (BCSCs) [110].